Next Article in Journal / Special Issue
Phosphorylation of the AMPAR-TARP Complex in Synaptic Plasticity
Previous Article in Journal
Early Responses to Severe Drought Stress in the Arabidopsis thaliana Cell Suspension Culture Proteome
Previous Article in Special Issue
Proteases Shape the Chlamydomonas Secretome: Comparison to Classical Neuropeptide Processing Machinery
Open AccessReview

Exploring Morphine-Triggered PKC-Targets and Their Interaction with Signaling Pathways Leading to Pain via TrkA

Department of Biochemistry, Chemistry Institute, University of São Paulo, Sao Paulo 05508-220, Brazil
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Authors to whom correspondence should be addressed.
Proteomes 2018, 6(4), 39;
Received: 24 August 2018 / Revised: 29 September 2018 / Accepted: 2 October 2018 / Published: 6 October 2018
(This article belongs to the Special Issue Neuroproteomics)
It is well accepted that treatment of chronic pain with morphine leads to μ opioid receptor (MOR) desensitization and the development of morphine tolerance. MOR activation by the selective peptide agonist, D-Ala2, N-MePhe4, Gly-ol]-enkephalin(DAMGO), leads to robust G protein receptor kinase activation, β-arrestin recruitment, and subsequent receptor endocytosis, which does not occur in an activation by morphine. However, MOR activation by morphine induces receptor desensitization, in a Protein kinase C (PKC) dependent manner. PKC inhibitors have been reported to decrease receptor desensitization, reduce opiate tolerance, and increase analgesia. However, the exact role of PKC in these processes is not clearly delineated. The difficulties in establishing a particular role for PKC have been, in part, due to the lack of reagents that allow the selective identification of PKC targets. Recently, we generated a conformation state-specific anti-PKC antibody that preferentially recognizes the active state of this kinase. Using this antibody to selectively isolate PKC substrates and a proteomics strategy to establish the identity of the proteins, we examined the effect of morphine treatment on the PKC targets. We found an enhanced interaction of a number of proteins with active PKC, in the presence of morphine. In this article, we discuss the role of these proteins in PKC-mediated MOR desensitization and analgesia. In addition, we posit a role for some of these proteins in mediating pain by TrKA activation, via the activation of transient receptor potential cation channel subfamily V member 1 (TRPV1). Finally, we discuss how these new PKC interacting proteins and pathways could be targeted for the treatment of pain. View Full-Text
Keywords: morphine; opioid receptors; conformational antibody; analgesia; GPCR signaling morphine; opioid receptors; conformational antibody; analgesia; GPCR signaling
Show Figures

Figure 1

MDPI and ACS Style

Pena, D.A.; Duarte, M.L.; Pramio, D.T.; Devi, L.A.; Schechtman, D. Exploring Morphine-Triggered PKC-Targets and Their Interaction with Signaling Pathways Leading to Pain via TrkA. Proteomes 2018, 6, 39.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop